The aim of this paper was to investigate the prognostic factors for local recurrence in patients with pathological fracture through giant cell tumours of bone (GCTB).

Patients and Methods

A total of 107 patients presenting with fractures through GCTB treated at our institution (Royal Orthopaedic Hospital, Birmingham, United Kingdom) between 1995 and 2016 were retrospectively studied. Of these patients, 57 were female (53%) and 50 were male (47%).The mean age at diagnosis was 33 years (14 to 86). A univariate analysis was performed, followed by multivariate analysis to identify risk factors based on the treatment and clinical characteristics.

Results

The initial surgical treatment was curettage with or without adjuvants in 55 patients (51%), en bloc resection with or without reconstruction in 45 patients (42%), and neoadjuvant denosumab, followed by resection (n = 3, 3%) or curettage (n = 4, 4%). The choice of treatment depended on tumour location, Campanacci tumour staging, intra-articular involvement, and fracture displacement. Neoadjuvant denosumab was used only in fractures through Campanacci stage 3 tumours. Local recurrence occurred in 28 patients (25%). Surgery more than six weeks after the fracture did not affect the risk of recurrence in any of the groups. In Campanacci stage 3 tumours not treated with denosumab, en bloc resection had lower local recurrences (13%), compared with curettage (39%). In tumours classified as Campanacci 2, intralesional curettage and en bloc resections had similar recurrence rates (21% and 24%, respectively). After univariate analysis, the type of surgical intervention, location, and the use of denosumab were independent factors predicting local recurrence. Further surgery was required 33% more often after intralesional curettage in comparison with resections (mean 1.59, 0 to 5 vs 1.06, 0 to 3 operations). All patients treated with denosumab followed by intralesional curettage developed local recurrence.

Conclusion

In patients with pathological fractures through GCTB not treated with denosumab, en bloc resection offers lower risks of local recurrence in tumours classified as Campanacci stage 3. Curettage or resections are both similar options in terms of the risk of local recurrence for tumours classified as Campanacci stage 2. The benefits of denosumab followed by intralesional curettage in these patients still remains unclear.

References

1. Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg [Am] 1987;69-A:106–114. Crossref, ISI, Google Scholar
2. Jeys LM, Suneja R, Chami G, et al. Impending fractures in giant cell tumours of the distal femur: incidence and outcome. Int Orthop 2006;30:135–138. Crossref, Medline, ISI, Google Scholar
3. van der Heijden L, Dijkstra PD, Campanacci DA, Gibbons CL, van de Sande MA. Giant cell tumor with pathologic fracture: should we curette or resect? Clin Orthop Relat Res 2013;471:820–829. Crossref, Medline, ISI, Google Scholar
4. Deheshi BM, Jaffer SN, Griffin AM, et al. Joint salvage for pathologic fracture of giant cell tumor of the lower extremity. Clin Orthop Relat Res 2007;459:96–104. Crossref, Medline, ISI, Google Scholar
5. Salunke AA, Chen Y, Chen X, et al. Does pathological fracture affect the rate of local recurrence in patients with a giant cell tumour of bone?: a meta-analysis. Bone Joint J 2015;97-B:1566–1571. Link, ISI, Google Scholar
6. McDonald DJ, Sim FH, McLeod RA, Dahlin DC. Giant-cell tumor of bone. J Bone Joint Surg [Am] 1986;68-A:235–242. Crossref, ISI, Google Scholar
7. Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res 2011;469:591–599. Crossref, Medline, ISI, Google Scholar
8. van der Heijden L, van de Sande MA, Dijkstra PD. Soft tissue extension increases the risk of local recurrence after curettage with adjuvants for giant-cell tumor of the long bones. Acta Orthop 2012;83:401–405. Crossref, Medline, ISI, Google Scholar
9. Gupta SP, Garg G. Curettage with cement augmentation of large bone defects in giant cell tumors with pathological fractures in lower-extremity long bones. J Orthop Traumatol 2016;17:239–247. Crossref, Medline, ISI, Google Scholar
10. Gaston CL, Bhumbra R, Watanuki M, et al. Does the addition of cement improve the rate of local recurrence after curettage of giant cell tumours in bone? J Bone Joint Surg [Br] 2011;93-B:1665–1669. Link, Google Scholar
11. Kivioja AH, Blomqvist C, Hietaniemi K, et al. Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop 2008;79:86–93. Crossref, Medline, ISI, Google Scholar
12. Turcotte RE, Wunder JS, Isler MH, et al. Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res 2002;397:248–258. Crossref, Google Scholar
13. Xing R, Yang J, Kong Q, et al. Giant cell tumour of bone in the appendicular skeleton: an analysis of 276 cases. Acta Orthop Belg 2013;79:731–737. Medline, ISI, Google Scholar
14. Arbeitsgemeinschaft Knochentumoren, Becker WT, Dohle J, et al. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg [Am] 2008;90-A:1060–1067. Google Scholar
15. Prosser GH, Baloch KG, Tillman RM, Carter SR, Grimer RJ. Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone? Clin Orthop Relat Res 2005;435:211–218. Crossref, ISI, Google Scholar
16. Blackley HR, Wunder JS, Davis AM, et al. Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg [Am] 1999;81-A:811–820. Crossref, ISI, Google Scholar
17. Dreinhöfer KE, Rydholm A, Bauer HC, Kreicbergs A. Giant-cell tumours with fracture at diagnosis. Curettage and acrylic cementing in ten cases. J Bone Joint Surg [Br] 1995;77-B:189–193. Link, Google Scholar
18. Su YP, Chen WM, Chen TH. Giant-cell tumors of bone: an analysis of 87 cases. Int Orthop 2004;28:239–243. Crossref, Medline, ISI, Google Scholar
19. Cheng DD, Hu T, Zhang HZ, Huang J, Yang QC. Factors affecting the recurrence of giant cell tumor of bone after surgery: a clinicopathological study of 80 cases from a single center. Cell Physiol Biochem 2015;36:1961–1970. Crossref, Medline, Google Scholar
20. Gaston CL, Grimer RJ, Parry M, et al. Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. Clin Sarcoma Res 2016;6:15. Crossref, Medline, ISI, Google Scholar

Vol. 100-B, No. 12

Metrics

Downloaded 442 times

History

Published online 30 November 2018

Published in print 1 December 2018

Information

Keywords

PDF download